Concepedia

Steffen Ventz

SV

Statistics

Publications

21

Citations

1.7K

H-Index

18

Active since

2014

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

University of Rhode Island

Center for Neuro-Oncology

Cancer Research And Biostatistics

Steffen Ventz is an author at Dana-Farber Cancer Institute specializing in clinical trials, biostatistics, and experimental design.

ORCID

Publications per year

2014–2022

21

Publications

21

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Nadine Tung, Mark E. Robson, Steffen Ventz et al. · Journal of Clinical Oncology · 2020 · 500 citations

, , +16

BRCA1 Recruitment to Transcriptional Pause Sites Is Required for R-Loop-Driven DNA Damage Repair

Elodie Hatchi, Konstantina Skourti-Stathaki, Steffen Ventz et al. · Molecular Cell · 2015 · 479 citations · Full text

, , +17

Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data

Steffen Ventz, Albert Lai, Timothy F. Cloughesy et al. · Clinical Cancer Research · 2019 · 85 citations

, , +17

Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications

Rifaquat Rahman, Geoffrey Fell, Steffen Ventz et al. · Clinical Cancer Research · 2019 · 78 citations

, , +14

TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).

Nadine Tung, Mark E. Robson, Steffen Ventz et al. · Journal of Clinical Oncology · 2020 · 60 citations

, , +16

1–5 of 21